[Ivacaftor (cystic fibrosis, 4 to < 6 months, gating mutation) - Benefit assessment according to §35a Social Code Book V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003822
German
Original Title:
Ivacaftor (zystische Fibrose, 4 bis < 6 Monate, mit Gating-Mutationen)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a20-100.html
Year Published:
2021
URL for published report:
https://www.iqwig.de/download/a20-100_ivacaftor_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Cystic Fibrosis
- Infant
- Chloride Channel Agonists
- Quinolones
Keywords
- Ivacaftor
- Cystic Fibrosis
- Infant
- Benefit Assessment
- NCT02725567
- NCT00909532
- NCT00909727
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.